Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado Trastuzumab Emtansine For Recurrent, Metastatic or Treatment Naïve, Unresectable HER-2 Positive Salivary Gland Cancer
NCT Number:
NCT05408845
Phase:
II
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Lip, Oral Cavity and Pharynx
Study Objectives:
To determine if trastuzumab emtansine (ado-trastuzumab emtansine [T-DM1]) shows better progression-free survival (PFS) when compared to docetaxel plus trastuzumab (TH) in recurrent and/or metastatic (R/M) HER2-positive salivary gland cancer (SGC) patients who have not previously received HER2 therapy for unresectable or recurrent and/or metastatic disease, as determined by local assessment.
Study Documents
(MUSC NetID required for document access)